ADT1134-Cinpanemab Biosimilar-(SNCA)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1134 |
Product Name |
ADT1134-Cinpanemab Biosimilar-(SNCA)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse SNCA antibody, anti-SNCA antibody, anti SNCA antibody, recombinant SNCA, SNCA antibody, anti-SNCA monoclonal antibody, SNCA antibodies, SNCA recombinant antibody, SNCA blocking antibody |
|
Alias |
PRX002, RG-7935 |
Host |
CHO Cells |
Species |
Human |
Target |
SNCA |
Gene ID |
6622 |
Isotype |
IgG1 Kappa |
Size |
1mg, 5mg |
Research Area |
Neurobiology |
CAS Number |
1960462-19-4 |
Product Description |
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease). |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Dauer, W., & Przedborski, S. (2003). “Parkinson’s disease: mechanisms and models.” Neuron, 39(6), 889-909. DOI: 10.1016/S0896-6273(03)00568-3.
2. Burre, J., et al. (2010). “Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.” Science, 329(5999), 1663-1667. DOI: 10.1126/science.1188910.
3. Kalia, L. V., & Lang, A. E. (2015). “Parkinson’s disease.” The Lancet, 386(9996), 896-912. DOI: 10.1016/S0140-6736(14)60456-9.
|